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Development of resistance causes failure of drugs
targeting receptor tyrosine kinase (RTK) networks
and represents a critical challenge for precisionmed-
icine. Here, we show that PHLDA1 downregulation is
critical to acquisition and maintenance of drug resis-
tance in RTK-driven cancer. Using fibroblast growth
factor receptor (FGFR) inhibition in endometrial can-
cer cells, we identify an Akt-driven compensatory
mechanism underpinned by downregulation of
PHLDA1. We demonstrate broad clinical relevance
of our findings, showing that PHLDA1 downregula-
tion also occurs in response to RTK-targeted therapy
in breast and renal cancer patients, as well as
following trastuzumab treatment in HER2+ breast
cancer cells. Crucially, knockdown of PHLDA1 alone
was sufficient to confer de novo resistance to RTK in-
hibitors and induction of PHLDA1 expression re-
sensitized drug-resistant cancer cells to targeted
therapies, identifying PHLDA1 as a biomarker for
drug response and highlighting the potential of
PHLDA1 reactivation as a means of circumventing
drug resistance.
INTRODUCTION
Improved understanding of the molecular mechanisms under-
pinning cancer has led to the development of an arsenal of ther-
apeutics, with which to tackle cancers driven by specific path-
ways. In particular, receptor tyrosine kinases (RTKs) have been
implicated in a wide variety of oncogenic behaviors, driving cell
proliferation, survival, migration, and mediating cancer cell-
stromal crosstalk (Gross et al., 2015). Small molecule kinase in-
hibitors and therapeutic antibodies targeted to RTKs can offer
clinically significant patient benefit (Slamon et al., 2001; Geyer
et al., 2006). However, the selective pressure applied on cancer
cells by targeting RTKs results in rapid evolution of resistanceCell Rep
This is an open access article undmechanisms, reducing the efficacy of targeted approaches
and resulting in tumor re-growth in patients (Engelman et al.,
2007; Kobayashi et al., 2005). Overcoming this acquired resis-
tance to targeted therapies represents a critical challenge for
cancer research (Holohan et al., 2013).
Fibroblast growth factor receptor (FGFR) signaling has been
implicated in both oncogenic and drug-resistance mechanisms
in many different cancers, and FGFR inhibitors are currently in
clinical trials for a range of cancer types (Carter et al., 2015).
Among these, endometrial cancer is ideal for exploring mecha-
nisms of resistance. The fourth most common form of cancer
in women, it highlights some very well-characterized FGFR
driver mutations, with up to 16% of cases driven by mutations
in FGFR2 (Fearon et al., 2013; Pollock et al., 2007). Herein, using
2D and 3D cultures of endometrial cancer cell lines expressing
either wild-type or mutant FGFR2 as model systems, we have
interrogated the mechanisms of acquired resistance to FGFR-
targeted ATP mimetic small molecule therapies (Mohammadi
et al., 1998; Gavine et al., 2012). Through gene expression
profiling, we have identified loss of the protein Pleckstrin Homol-
ogy-Like Domain, family A, member 1 (PHLDA1) as a critical
mediator of resistance to FGFR inhibition and validated these
studies by manipulating PHLDA1 expression. Using phospho-
proteomics and combination drug treatment, we show that Akt
signaling is critical to this acquired resistance, and we present
a model for how PHLDA1 may mediate this effect. Finally, we
have extrapolated our findings to other RTK-driven cancers, us-
ing cell-based, in vivo and bioinformatics approaches, to identify
PHLDA1 as a mediator of resistance with direct relevance to a
broad range of RTK-targeted therapies.
RESULTS
Development of Drug Resistance in Endometrial Cancer
Cells
To investigate mechanisms of acquired resistance to FGFR in-
hibitors, we adopted endometrial cancer cell line models, with
two cell lines that harbor FGFR2 activating mutations,
MFE-296 and AN3CA cells (Byron et al., 2008), and one that ex-
presses wild-type FGFR2, Ishikawa cells (Byron et al., 2013).orts 22, 2469–2481, February 27, 2018 ª 2018 The Author(s). 2469
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Generation of FGFR Inhibitor-Resistant Endometrial Can-
cer Cell Populations In Vitro
(A) Western blot analysis of FGFR2 and phosphorylated FRS2a (Tyr436) in
serum-starved MFE-296, AN3CA, and Ishikawa cells. Data are representative
of three independent experiments.
2470 Cell Reports 22, 2469–2481, February 27, 2018MFE-296 and AN3CA cells expressed high levels of FGFR2,
relative to Ishikawa cells, and exhibited enhanced levels of phos-
phorylated FGFR substrate 2 (FRS2), an indicator of FGFR acti-
vation, reflecting their dependence on basal FGFR activation
(Figure 1A). Ishikawa cells express wild-type FGFR and thus
have minimal phosphorylated FRS2 under normal conditions.
To model FGFR inhibition in a physiologically relevant context,
where cancer cells receive stromal support, 3D organotypic
models (Chioni et al., 2017) were used (Figure 1). Collagen/
Matrigel gels were overlaid with MFE-296, AN3CA, or Ishikawa
cells and treated with FGFR inhibitors for 14 days. Treatment
with PD173074, an ATP-competitive inhibitor of FGFR (Moham-
madi et al., 1998), resulted in a significant reduction in cell num-
ber in MFE-296 and AN3CA cells, while Ishikawa cells remained
unaffected (Figures 1B–1D). Quantitation of cell number and the
percentage of Ki67-expressing cells following treatment re-
vealed that AN3CA cells were almost absent following treatment
with PD173074 (Figure 1C). In contrast, by day 14 of treatment,
MFE-296 cells established a population of proliferating cells in
the presence of PD173074, albeit reduced compared to DMSO
control cultures (Figure 1B), suggesting the emergence of a
resistant cell population. Comparable data were obtained using
AZD4547, another ATP-competitive inhibitor of FGFR currently
in clinical trials for FGFR2 mutant solid tumors (Carter et al.,
2015; Gavine et al., 2012) (Figure S1).
To investigate the mechanism underlying sustained FGFR in-
hibitor resistance, FGFR-inhibitor-resistant populations of MFE-
296 and AN3CA cells (MFE-296AZDR and AN3CAAZDR, respec-
tively) were generated by increasing exposure to AZD4547.
When cultured on mini-organotypic gels for 7 days in the pres-
ence of 1 mM AZD4547, both populations of resistant cells
showed significantly less reduction in proliferation rate compared
to parental cells (Figures S1A and S1B). Drug sensitivities were
confirmed in 2D culture using an IncuCyte platform and demon-
strate that AN3CA cells exhibit enhanced sensitivity to both
PD173074 and AZD4547 over MFE-296 cells, as previously
reported (Packer et al., 2017) (Figures S1C–S1F). Further, both
AN3CAAZDR and MFE-296AZDR exhibited cross-resistance to
PD173074 (Figures S1D and S1F). As expected, Ishikawa cell
growth was unaffected by both FGFR inhibitors (Figure S1G)
Phosphoproteomic Interrogation of Resistance
Acquisition in MFE-296 Cells
To understand how resistant cells are able to re-engage prolifer-
ative pathways, we examined changes to the phosphoproteome
of MFE-296 cells, as they developed resistance to PD173074
over 14 days of culture.
Phosphorylation sites were identified and quantified using a
well-established, label-free methodology (Alcolea et al., 2012;(B–D) Upper: H&E staining of MFE-296 (B), AN3CA (C), and Ishikawa (D) cells
grown in organotypic cultures for 14 days with or without 1 mM PD173074.
Lower: Ki67 staining with nuclei counterstained by DAPI. Right: quantitation of
cell number and Ki67 positive nuclei per field of view.
Data are presented asmean ±SEM. Images are representative of at least three
independent experiments. H&E image scale bar, 100 mm; Ki67 image scale
bar, 50 mm. ***p % 0.001, compared with DMSO controls. H&E images are
automatically spliced composites.
Figure 2. Phosphoproteomic Analysis of Endometrial Cancer Cell
Lines Identifies a Pivotal Role for Akt Signaling in FGFR Inhibitor
Resistance
(A) Dendrogram of the hierarchical clustering (Pearson correlation distance
metric) of phosphoproteomic signatures obtained through mass spectrometryCasado et al., 2013; Wilkes et al., 2015). Hierarchical clustering
of the resulting phosphorylation motifs demonstrated a high de-
gree of similarity in the phosphoproteome between the start of
treatment and that after 14 days of culture with PD173074.
Intriguingly, the phosphoproteome of PD173074-treated cells
was noticeably divergent from that of controls at 7 days of treat-
ment, suggesting a global change in cell signaling (Figure 2A).
Of the 6,706 phosphopeptides identified, 525 were signifi-
cantly up- or downregulated in samples from cells treated with
PD173074, compared to DMSO controls, for at least one time
point. These phosphopeptides were grouped according to their
temporal profile (Figure S2A). Interestingly, 412 phosphopepti-
des were downregulated at 7 days treatment with PD173074
and returned to baseline levels after 14 days (Figure 2B).
Kinase substrate enrichment analysis (KSEA) (Casado et al.,
2013) was used to determine the upstream kinases of the iden-
tified phosphopeptides. This approach identified an enrichment
of Akt and Akt-related effectors (Figure S2A), indicating re-
establishment of Akt signaling following an initial FGFR inhibi-
tor-induced dampening of the pathway (Figures S2A and S2B).
Supporting this, western blotting of cell lysates isolated from
MFE-296 cells treated with PD173074 for up to 14 days
confirmed that, while total Akt levels remained constant, there
was a clear decrease in the levels of pAkt (Ser473), an indicator
of Akt activity, which returned to normal within 13 days of
continued treatment (Figure 2C).
To investigate the importance of Akt signaling in resistance,
MFE-296PDR cells were treated for 14 days with 1 mM
PD173074, either alone or in combination with 1 mM MK2206,
an allosteric pan-Akt inhibitor (Hirai et al., 2010), in organotypic
models. This combination treatment reduced cell number and
proliferation significantly, compared to single treatment alone
(Figure 2D). In contrast, Ishikawa cells (FGFR2 wild-type) were
unaffected by drug combination treatment (Figure 2D), indicating
that the effects of PD173074/MK2206 treatment seen in
MFE-296 cells were FGFR2 dependent. These data suggest
that resurgence of Akt signaling mediates resistance to FGFR
inhibition.
Determining the Mechanism of FGFR Inhibitor
Resistance in MFE-296 Cells
To investigate gene expression changes associated with FGFR
inhibitor resistance, MFE-296, MFE-296AZDR and MFE-296PDRof MFE-296 cells treated with DMSO, 1 mM PD173074 (PD), or untreated (UT)
over 1, 7, and 14 days.
(B) Representation of changes in the phosphoproteome of MFE-296 cells
treated with 1 mMPD173074 compared to DMSO controls at 1, 7, and 14 days.
(C) Western blot showing changes in pAkt (Ser473) induced by treatment of
MFE-296 cells with 1 mM PD173074 over 14 days. Data are representative of
three independent experiments.
(D) Left: H&E staining and Ki67 staining of MFE-296PDR cells (upper) and
Ishikawa cells (lower) grown in organotypic cultures for 7 days. Cells were
cultured in 1 mMPD173074with or without 1 mMMK2206. Right: quantitation of
cell number and Ki67 positive nuclei.
Data are presented asmean ±SEM. Images are representative of at least three
independent experiments. H&E images scale bar, 100 mm; Ki67 images scale
bar, 50 mm. ***p % 0.001, **p % 0.01. H&E images are automatically spliced
composites.
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cells were assayed in duplicate using an Illumina platform. We
identified 587 probes, corresponding to 522 genes, that were up-
regulated and 543 probes, corresponding to 485 genes, that
were downregulated in MFE-296PDR cells compared to the
parental cell line. Among the top ten downregulated genes
(Figure 3A) were several known FGFR signaling targets, including
Sprouty 4 (SPRY4) and Dual specificity phosphatase 6 (DUSP6)
(Li et al., 2007; Yang et al., 2006). Similarly, among the upregu-
lated genes (Figure S3A), IGFBP5 was identified, the expression
of which is known to be elevated in the absence of FGFR2 in
keratinocytes in vivo (Grose et al., 2007; Schlake, 2005). Interest-
ingly, MFE-296PDR and MFE-296AZDR cells displayed strikingly
similar changes in gene expression profile (Figures 3A, S3A,
and S3B). The gene most significantly downregulated in both
cell sub-populations was PHLDA1 (Figure 3A).
PHLDA1 protein levels were decreased significantly in parental
MFE-296 cells upon treatment with 1 mM AZD4547 or PD173074
for 7 days, and PHLDA1 protein was absent from MFE-296AZDR
and MFE-296PDR cells, even following culture in drug-free me-
dium (Figures 3B and S3C). These data were recapitulated in
AN3CA and AN3CAAZDR cells (Figure 3C), suggesting that stable
downregulation of PHLDA1 levels is a common response to
FGFR inhibition in these FGFR2-driven cancer cell lines. In line
with this, PHLDA1 levels were unaffected in FGFR2wild-type Ish-
ikawa cells following PD173074 treatment (Figure 3D).
We next sought to determine whether PHLDA1 could regulate
the activity of Akt, as has been previously implicated (Durbas
et al., 2016; Li et al., 2014), thus providing a link between our pro-
teomic and microarray datasets. Expression of a GFP-tagged
PHLDA1 construct in the breast cancer cell line HCC1954
reduced the levels of pAkt (S473), suggesting negative regulation
of Akt activation (Figure 3E). We also generated a mutant
PHLDA1 construct wherein amino acid residues 152–159 and
167–171, corresponding to the predicted sites required for phos-
phatidyl-3, 4, 5-trisphosphate (PIP3) binding (Kawase et al.,
2009), have been removed. This construct failed to localize to
the cell membrane, unlike the wild-type counterpart, suggesting
a requirement of a functional PH domain in the function of
PHLDA1 (Figures 3F and 3G).
Knockdown of PHLDA1 Confers Resistance to FGFR
Inhibition
Having identified PHLDA1 as a significantly downregulated gene
in resistant cell populations, we examined whether PHLDA1 loss
alone was sufficient to confer resistance in parental cell lines. We
engineered four lentiviral short hairpin RNA (shRNA) constructsFigure 3. PHLDA1 Negatively Regulates Akt and Is Downregulated in F
(A) Top ten downregulated genes in MFE-296PDR cells (left) and MFE-296AZDR ce
(B–D) Western blot showing downregulation of PHLDA1 levels in parental MFE-29
persistent downregulation of PHLDA1 in MFE-296AZDR and AN3CAAZDR cells follo
were unaffected by FGFR inhibitor treatment.
(E) Left: western blot showing reduced p-Akt (pSer473) in HCC1954 cells follo
normalized to total Akt and GAPDH. Data are presented as mean fold change ±S
(F) MFE-296 cells were transfected with constructs encoding GFP-PHLDA1, GFP
DAPI, and F-actin was visualized using Alexa Fluor 546 Phalloidin (red). Scale ba
(G) Domain organization of PHLDA1.
PH domain, pleckstrin homology domain; QQ, polyglutamine tract; P-Q, prolin
mtPHLDA1 are indicated in red.(three targeting PHLDA1 and one scrambled non-targeting
control) and generated cell lines stably expressing each shRNA.
After 14 days of culture, MFE-296 cells expressing scrambled
shRNA sequences showed a marked reduction in cell number
when exposed to 1 mM AZD4547, compared with DMSO con-
trols (Figure 4A). Proliferation was unaffected between treated
and untreated scrambled shRNA cells at 14 days of culture, indi-
cating the scrambled controls had developed resistance akin to
wild-type cells. Strikingly, this AZD4547 induced reduction in cell
number was ameliorated significantly when PHLDA1 shRNA
sequences were expressed, suggesting the acquisition of
de novo resistance (Figure 4A). Effective knockdown of PHLDA1
at the protein level in MFE-296 cells was confirmed prior to
embedding cells into mini-organotypic gels (Figure 4B).
Recovery of PHLDA1 Expression Re-sensitizes
Resistant Cells to FGFR Inhibitors
Having determined that PHLDA1 downregulation was associ-
ated with an ability to grow in the presence of FGFR inhibitor,
we investigated whether rescuing the expression of PHLDA1
was sufficient to re-sensitize cells resistant to FGFR inhibitors.
Full-length human PHLDA1was cloned into a doxycycline induc-
ible lentiviral construct and transduced into parental and
AZD4547-resistant AN3CA and MFE-296 cells. As expected,
parental AN3CA cells remained exquisitely sensitive to
AZD4547, irrespective of PHLDA1 overexpression (Figure 5A,
upper panel). However, AN3CAAZDR cells, which showed similar
growth in 1 mM AZD4547 as parental AN3CA cells did in the
absence of drug, were completely re-sensitized to both FGFR in-
hibitors through the induction of PHLDA1 expression (Figure 5A,
lower panel). Moreover, PHLDA1 induction in resistant cells in
the absence of drug had no effect on cell growth (Figure S4).
Efficacy of PHLDA1 induction was confirmed by western blot
(Figure 5B), and the data were recapitulated in MFE-296 cells
(Figures 5C and 5D), confirming that re-expression of PHLDA1,
while having no effect on non-FGFR-inhibitor-treated cells,
was sufficient to re-sensitize drug-resistant cells.
PHLDA1 Mediates Resistance to RTK-Targeted
Therapies in Breast Cancer
Having determined that PHLDA1 downregulation can underpin
tyrosine kinase inhibitor resistance in endometrial cancer cell
lines, we investigated whether this was a more global phenome-
non in resistance to RTK-targeted therapy.We examined Human
Epidermal Growth Factor Receptor 2 (HER2) positive breast can-
cers as not only is this RTKoverexpressed in 25%–30%of breastGFR Inhibitor-Resistant Endometrial Cancer Cell Lines
lls (right) compared to parental controls, identified by microarray analysis.
6 (B) and AN3CA (C) cells following treatment with 1 mMAZD4547 for 24 hr and
wing removal of 1 mM AZD4547 for 24 hr. PHLDA1 levels in Ishikawa cells (D)
wing transfection with GFP-PHLDA1. Right: quantitation of p-Akt (Ser473),
EM in p-Akt (Ser473) ***p% 0.001.
-mtPHLDA1, or GFP-PH-Akt for 48 hr prior to fixation. Nuclei were labeled with
r, 50 mm.
e-glutamine rich tract; P-H, proline-histidine rich tract. Residues deleted in
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Figure 4. PHLDA1 Downregulation Confers De Novo Resistance to FGFR Inhibitors
(A) Upper: H&E staining of MFE-296 cells expressing either scrambled or PHLDA1 shRNA, grown in mini-organotypic cultures for 14 days with or without 1 mM
AZD4547. Lower: Ki67 staining with nuclei counterstained by DAPI. Images are representative of three independent experiments conducted with three distinct
shRNA sequences. Right: quantitation of cell number and percentage of Ki67 positive nuclei. Data are presented as mean ± SEM. H&E image scale bar, 100 mm;
Ki67 image scale bar, 50 mm. ***p% 0.001. H&E images are automatically spliced composites.
(B) Western blot analysis of PHLDA1 levels in MFE-296 expressing either scrambled or PHLDA1 shRNA.cancers, but also 70% of patients develop resistance to the cur-
rent frontline therapy, the HER2-targeted monoclonal antibody,
trastuzumab (Moore et al., 2014; Slamon et al., 2001).
PHLDA1 levels were reduced significantly in the HER2+ breast
cancer cell line, MCF7/HER2-18 (Yu et al., 1996), following expo-
sure to trastuzumab (Figure 6A). Similar to endometrial cancer
cells, knockdown of PHLDA1 alone, by 48-hr treatment with
small interfering RNA (siRNA), was sufficient to generate
de novo resistance to trastuzumab (Figures 6B and S5A).
To examine this further in an in vivo setting, MCF7/HER2-18
cells were injected subcutaneously into immunodeficient mice,
which subsequently received biweekly intraperitoneal injections
of trastuzumab or immunoglobulin G (IgG) control for 4weeks, as
outlined previously (Moore et al., 2014). In situ hybridization for
PHLDA1 showed significantly decreased mRNA levels upon
trastuzumab treatment (Figure 6C), suggesting that downregula-
tion of PHLDA1 might be a common response to RTK inhibition
in vitro and in vivo.
In support of this, we determined the importance of PHLDA1
expression in parental and lapatinib-resistant populations of
two further HER2+ breast cancer cell lines, SKBR3 and
HCC1954. These resistant cell lines were generated through
exposure to increasing concentrations of lapatinib and showed
a marked reduction in sensitivity to lapatinib compared to
parental counterparts (Figure S5B–S5E). In both lines, lapati-
nib-resistant populations showed a dramatic decrease in2474 Cell Reports 22, 2469–2481, February 27, 2018PHLDA1 protein levels (Figure 6D). Rescue of PHLDA1 in mini-
organotypic models, using the same doxycycline inducible
approach as above, led to a significant decrease in cell prolifer-
ation in lapatinib-resistant cell lines (Figures 6E–6H). Importantly,
both SKBR3 and HCC1954 parental lines showed exquisite
sensitivity to lapatinib treatment and were unaffected by induc-
tion of PHLDA1 above baseline levels (Figures S5F and S5G).
Again, these data demonstrate that re-expression of PHLDA1
alone is sufficient to re-sensitize cells to RTK inhibition.
Since the development of RTKi resistance in our endometrial
cancer model was dependent on a resurgence in Akt activity
(Figure 2D), we examined whether the re-sensitization of resis-
tant cells following PHLDA1 induction was mediated by a
suppression of Akt signaling. Indeed, induction of PHLDA1
expression in both endometrial and breast cancer models re-
sulted in amarked decrease in Akt phosphorylation (Figure S6A).
This regulation of Akt activation was shown to be dependent on
PHLDA1 PH domain function, since induction of mtPHLDA1 did
not affect pAkt (Ser473) levels (Figure S6B). Importantly,
HCC1954LapR cells could not be re-sensitized to lapatinib treat-
ment by expression of mtPHLDA1 (Figure S6C).
Human Tumors Treated with RTK Inhibitors Show Lower
PHLDA1 Expression Compared to Untreated Controls
To investigate whether PHLDA1 expression is downregulated in
human tumors treated with RTK inhibitors, three Affymetrix
Figure 5. Recovery of PHLDA1 Expression
Re-sensitizes Resistant Cells to FGFR Inhib-
itors
(A and C) Upper: H&E staining of parental and
AZD4547-resistant AN3CA (A) and MFE-296 cells
(C) containing a doxycycline-inducible PHLDA1
expression construct. Cells were grown in mini-
organotypic cultures for 7 dayswith orwithout 1mM
AZD4547 and 0.2 mg/mL doxycycline. Lower: Ki67
staining with nuclei counterstained by DAPI. Right:
quantitation of cell number and percentage of Ki67
positive nuclei. Data are presented asmean±SEM.
Images are representative of at least three inde-
pendent experiments. H&E image scale bar,
100 mm; Ki67 image scale bar, 50 mm. ***p% 0.001.
H&E images are automatically spliced composites.
(B and D) Western blot showing PHLDA1 levels in
parental and resistant AN3CA cells (B) and
MFE-296 cells (D) following doxycycline treatment.
Data are representative of three independent
experiments.datasets were obtained from the NCBI GEO database and the
expression of PHLDA1 was compared between treated and un-
treated tumor samples. We examined locally advanced non-
metastatic renal tumors treatedwith the PDGFR/VEGFR inhibitor
sunitinib, metastatic breast cancers treated with docetaxel in
combination with sunitinib, and metastatic ER+ breast tumors
treated with tamoxifen in combination with the PDGF/VEGFR/Cell RepoRas/Raf/MAPK inhibitor sorafenib (Fig-
ure S5H). In all cases, patients treated
with an RTK inhibitor exhibited reduced
PHLDA1, suggesting that PHLDA1 down-
regulation occurs in response to RTK inhi-
bition in multiple tumor types.
DISCUSSION
Targeted therapies entering the clinic pro-
vide a powerful means to treat RTK-driven
cancers. However, with this comes the
challenge of cancers developing resis-
tance, rendering the therapy ineffective
(Holohan et al., 2013; Garraway and
Ja¨nne, 2012; Glickman and Sawyers,
2012). Identifying markers predictive of
patient response to treatment, and
methods to circumvent resistance, are
thus of great importance for the continued
use of targeted approaches in cancer
treatment.
Here, we have utilized endometrial can-
cer cell lines harboring driver mutations in
FGFR2 (Byron et al., 2008; Dutt et al.,
2008; Pollock et al., 2007) as a platform
to identify mechanisms of tyrosine kinase
inhibitor (TKI) resistance. As FGFR muta-
tions account for approximately 16% of
endometrial cancers, they present anattractive target for therapy either as single agents or in combi-
nation with conventional chemotherapy (Byron et al., 2012;
Konecny et al., 2013). However, due to a high prevalence of
chemotherapy resistance in endometrial cancer (Chaudhry and
Asselin, 2009), the potential impact of FGFR therapies is
challenged. MFE-296 cells readily acquired resistance to the
FGFR inhibitors PD173074 and AZD4547 following continuedrts 22, 2469–2481, February 27, 2018 2475
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exposure in 2D and 3D cultures. AN3CA cells were consistently
more sensitive to FGFR inhibition but nevertheless developed
resistance to FGFR inhibitors through persistent exposure.
Acquisition of resistance to FGFR inhibitors has been
reported previously (Packer et al., 2017), but the mechanistic
basis of this remains to be elucidated. Through phosphopro-
teomic analysis of resistant cells, we identified a recovery in
Akt-mediated signaling following FGFR inhibition. Recovery of
the PI3K/Akt pathway has previously been suggested as a
driver of resistance following RTK inhibition (Goltsov et al.,
2011), and this is also true for FGFR-driven cancers (Singleton
et al., 2015; Wang et al., 2017; Datta et al., 2017; Packer et al.,
2017). Crucially, inhibition of FGFR and Akt signaling in our
models was sufficient to prevent the acquired resistance to
FGFR inhibition, demonstrating that recovery of Akt signaling
confers resistance to FGFR inhibition.
PI3K/Akt signaling is frequently deregulated in cancer, making
inhibition of this pathway an attractive approach (Foster et al.,
2012). However, cancers are also capable of developing resis-
tance to PI3K directed therapies, which are often mediated
through the MEK pathway, another prominent driver of cell
growth and survival (Hoeflich et al., 2009; Wee et al., 2009).
Thus, combination treatments are a potential method to over-
come resistance to a single agent. This approach has been
demonstrated to be effective with combined treatments of
PI3K and MEK-targeted therapeutics, but at the expense of
severe dose-limiting toxicities (Shimizu et al., 2012). A more
effective strategy will therefore arise from the identification,
and therapeutic targeting, of novel resistance pathways that
are not themselves critical for normal cell function.
To determine the changes in gene expression that under-
pinned the recovery in Akt signaling, we compared gene expres-
sion profiles of MFE-296 endometrial cancer cells, resistant to
two distinct FGFR inhibitors, with that of parental cells. The
most striking result from our microarray analysis was that, in
both populations of resistant endometrial cancer cell lines, the
Pleckstrin Homology-Like Domain-containing protein, PHLDA1,
was the most strongly downregulated gene. PHLDA1 has been
shown to negatively regulate Akt activation (Durbas et al.,
2016; Li et al., 2014), and the concurrent downregulation of
PHLDA1 and resurgence of Akt signaling observed in our model
suggested a role for PHLDA1 loss in the development of TKI
resistance. Indeed, our experiments showed that PHLDA1
downregulation is critical for resistance to FGFR inhibition; not
only does PHLDA1 knockdown confer de novo resistance inFigure 6. PHLDA1 Levels Regulate Sensitivity to Trastuzumab and Lap
(A) Western blot analysis of PHLDA1 levels in MCF7/HER2-18 cells cultured with
(B) MCF7/HER2-18 cell number following 3-day treatment with 1 mM trastuzuma
(C) In situ hybridization for PHLDA1 expression in MCF7/HER2-18 xenograft tumo
PHLDA1 mRNA expression (brown), whereas treatment with trastuzumab result
counterstained with hematoxylin, and dotted boxes represent zoomed-in are
condition. *p% 0.05, **p% 0.01, compared with IgG controls.
(D) Western blot showing PHLDA1 levels in parental and lapatinib-resistant SKB
(E and G). Upper: H&E staining of SKBR3LapR (E) and HCC1954LapR cells (G) conta
in mini-organotypic cultures for 7 days with or without 2 mM lapatinib and 1 mg/m
quantitation of cell number and Ki67-positive nuclei. Data are presented as mean
H&E image scale bar, 100 mm; Ki67 image scale bar, 50 mm. ***p% 0.001. H&E
(F and H) Western blot showing PHLDA1 levels in parental and resistant SKBR3parental cell lines, but re-expression in resistant lines is sufficient
to re-sensitize cells to FGFR inhibition.
Despite the robust effect on resistance of manipulating
PHLDA1 in our model systems, other genes identified in our mi-
croarray analysis may be involved in resistance. Indeed, DUSP6
downregulation has been implicated in resistance to EGFR-tar-
geted therapy in lung cancer (Phuchareon et al., 2015). However,
this resistancemechanismwas driven through the reactivation of
the ERK pathway despite the continued suppression of Akt,
whereas in our system resurgence in Akt signaling is required
for resistance.
Our data also suggest that PHLDA1 loss in resistance is not
a response restricted to FGFR inhibition but may reflect a
more global mechanism of resistance to RTK inhibition.
PHLDA1 loss is able to confer resistance to trastuzumab in
both in vitro and in vivo models of HER2+ breast cancer. More-
over, as with our endometrial cancer cell lines, re-expression
of PHLDA1 re-sensitizes lapatinib-resistant HER2+ breast can-
cer cells. PHLDA1 loss has been observed in response to
HER2-targeted therapy (Li et al., 2014), but here we demon-
strate that loss of PHLDA1 alone is sufficient to account for
this resistance. Mining publically available clinical datasets,
we identified expression of PHLDA1 in breast and renal tumors
from patients treated with PDGFR/VEGFR inhibitors, either
alone or in combination with other therapies, was significantly
lower than in tumors from patients treated with chemotherapy
or hormone therapy alone, further supporting a broader role
for PHLDA1 loss as a mechanism of resistance to kinase
inhibitors.
PHLDA1 was originally identified as a pro-apoptotic protein
involved in T cell receptor activation-induced apoptosis (Frank
et al., 1999; Park et al., 1996) and has since been shown to inhibit
cell proliferation and invasion in a number of cell types (Bonatto
et al., 2017; Johnson et al., 2011; Neef et al., 2002; Oberst et al.,
2008; Gomes et al., 1999). The mechanistic basis for these
cellular functions of PHLDA1 is largely unknown. The PHLDA1
PH domain shares high sequence homology with the PH domain
of the related protein PHLDA3, which has been shown to
compete with Akt for binding to PIP3 (Kawase et al., 2009). We
have demonstrated that PHLDA1 expression is capable of sup-
pressing Akt activity and also localizes to the plasma membrane
in a PH-domain-dependent manner, suggesting that PHLDA1
can regulate Akt in a similar fashion to PHLDA3. Our data,
together with these published findings, support a model where
loss of PHLDA1 during sustained TKI treatment allows foratinib Treatment
1 mM trastuzumab or IgG control for 72 hr.
b preceded by 48-hr siRNA knockdown of PHLDA1 or scrambled control.
rs. Four-week-old tumors frommice treated with an IgG control showed strong
ed in significantly weaker staining, as shown in graph on right. Sections were
as. Data are presented as mean ± SEM from at least eight mice for each
R3 and HCC1954 cells treated with 2 mM lapatinib or DMSO control for 48 hr.
ining a doxycycline-inducible PHLDA1 expression construct. Cells were grown
L doxycycline. Lower: Ki67 staining with nuclei counterstained by DAPI. Right:
± SEM. Images are representative of at least three independent experiments.
images are automatically spliced composites.
cells (F) and HCC1954 cells (H) following treatment with doxycycline.
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Figure 7. Model for PHLDA1 Silencing as a Mechanism of Acquired Drug Resistance
In normal growth conditions (left), strong PI3K activity results in generation of ample PIP3 at the cell membrane. This enables the recruitment of Akt and PDK1 (not
shown), resulting in Akt phosphorylation and subsequent activation. PHLDA1 can buffer this signaling by competing for free PIP3.When RTK activity is blocked by
pharmacological inhibition (right), PI3K activity is reduced, leading to a reduction in free PIP3. This results in decreased Akt signaling, and reduced cell division/
survival. Cells can establish resistance by silencing PHLDA1 expression, thus removing the competition for free PIP3 binding. This would allow Akt signaling to
recover, even in the absence of a strong RTK driver.sufficient Akt recruitment to residual PIP3 in order tomaintain cell
proliferation and survival (Figure 7).
It remains to be determined whether initial PHLDA1 expres-
sion in a tumor influences the response to treatment andwhether
this can be used to identify patients who are likely to develop
resistance. The potential for PHLDA1 as a prognostic factor in
cancer appears to be context specific, as high expression is
associated with poor prognosis in ER+ breast cancers (Kastrati
et al., 2014), and contributes to intestinal and pancreatic tumor-
igenesis (Oberg et al., 2004; Sakthianandeswaren et al., 2011),
while low expression is a poor indicator in ER– cancers (Johnson
et al., 2011; Nagai et al., 2007), and is linked with cancer progres-
sion inmelanoma (Neef et al., 2002) and gastric adenocarcinoma
(Zhao et al., 2015).
Wehave identifiedPHLDA1downregulationasamechanismby
which cancer cells can develop resistance to RTK-targeted ther-
apy. Our data support a model whereby co-activation of down-
stream signaling pathways leads to drug resistance (Stommel
et al., 2007). We propose that, by lowering PHLDA1 levels, the
threshold level of PIP3 required for sufficient Akt activation is
reduced, allowing the relatively weaker PI3K activity downstream
of alternative RTKs to generate sufficient signaling to support cell
proliferation. Thus, PHLDA1 may represent a useful biomarker to
identify patients who will develop resistance to cancer therapeu-
tics, and targetingPHLDA1 regulationpresentsanattractive pros-
pect for preventing drug resistance in cancer patients.
EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
3D Organotypic Model
Organotypic cultures were prepared following a modified version of a previ-
ously published protocol (Chioni and Grose, 2012). Briefly, collagen/Matrigel
gels containing 53 105 human foreskin fibroblasts (HFF2) cells/mL were over-
laid with 1 3 106 cancer cells/mL and raised to an air-liquid interface upon a
nylon-membrane covered metal grid in a 6-well plate. At the relevant time
point, gels were fixed in 10% neutral buffered formalin, bisected and dehy-
drated in 70% ethanol before paraffin embedding.2478 Cell Reports 22, 2469–2481, February 27, 2018The mini-organotypic model was modified from a previously described pro-
tocol (Coleman et al., 2014). A collagen/Matrigel gel containing 6.25 3 104
HFF2 cells was prepared in a 24-well plate transwell insert (Corning, 3412)
and overlaid with 1.25 3 105 cancer cells. Cells were left to adhere to the gel
then subsequently cultured at the air-liquid interface. Gels were formalin fixed,
paraffin embedded and sectioned as described above.
Western Blotting
Cell lysates were prepared using RIPA buffer (Millipore) supplemented with
protease (Millipore) and phosphatase (Millipore) inhibitor cocktails. Dena-
tured proteins (20–40 mg) were separated by electrophoresis on 4%–12%
Bis-Tris gels (NuPAGE Novex; Invitrogen). Proteins were subsequently trans-
ferred onto nitrocellulose membranes, blocked with 5% milk, and incubated
with primary antibody, diluted 1:1,000 in 3% BSA/PBS. All antibodies were
rabbit polyclonal unless otherwise stated: anti-Akt (Cell Signaling Technol-
ogy, 9272S), anti-ERK (Millipore, 06-182), anti-FGFR2 (Santa Cruz, sc-122),
anti-FRS2 (Santa Cruz, sc-8318), anti-HSC70 (mouse monoclonal; Santa
Cruz, sc-7298), anti-p-Akt (Ser473) (Cell Signaling Technology, 9271S),
anti-p-ERK (Thr202/Tyr204) (Cell Signaling Technology, 9101S), anti-p-
FRS2 (Cell Signaling Technology, 3861), anti-PHLDA1 (Abcam, ab133654).
Membranes were then incubated with a species appropriate horseradish
peroxidase (HRP)-conjugated secondary antibody (DAKO) before bands
were visualized using an enhanced chemiluminescence detection kit (GE
Healthcare).
Mass Spectrometry
MFE-296 cells were plated at 7 3 105 cells per 10-cm dish and either left un-
treated or cultured with DMSO as a vehicle control, or 1 mM PD173074. Cells
were lysed at 1, 7, or 14 days. Cell lysis, digestion, solid-phase extraction, TiO2
Metal Oxide Affinity Chromatography, Nanoflow-liquid chromatography
tandem mass spectrometry, and identification and quantification of phospho-
peptides were performed as previously described (Wilkes et al., 2015).
Gene Expression Microarray
Microarray gene expression analysis of cDNA from two biological replicates of
each cell line was performed using the Illumina HT12v platform at Barts
Genome Centre. Each sample was run on the array in duplicate. The resulting
data were analyzed using Illumina Genome Studio software. Within the soft-
ware, data quality control, filtering, and normalization were performed across
samples. Differential expression analyses between the two biological groups
were further conducted. Significantly differentially expressed geneswere iden-
tified based on the adjusted p value <0.05 using Bonferroni correction. The
gene expression microarray data have been deposited to GEO using the
accession number GSE81169.
Tumor Xenografts
Female SCIDmice were subcutaneously injected with MCF7/HER2-18 cells at
6–8 weeks of age (Moore et al., 2014). Mice were randomized into treatment
groups based on tumor volume (nR 3/treatment) and administered biweekly
intraperitoneal injections (10 mg/kg in 200 mL of PBS) of human IgG or trastu-
zumab for 4 weeks. Tumors were harvested and fixed as described previously,
and 5-mm wax sections were processed for in situ hybridization. All mouse
experiments followed Home Office Guidelines determined by the Animals
(Scientific Procedures) Act 1986.
DATA AND SOFTWARE AVAILABILITY
The accession number for all microarray datasets reported in this paper is
GEO: GSE81169. The dataset identifier for the mass spectrometry proteomics
is ProteomeXchange Consortium via the PRIDE (Vizcaı´no et al., 2016) partner
repository: PXD008859.
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